Archives
-
PBS (Phosphate-Buffered Saline): Lab Guide
2026-08-25
PBS (Phosphate-Buffered Saline), SKU K2818, provides a sterile, ready-to-use isotonic buffer for cell washing, reagent dilution, and compatible in vitro workflows requiring controlled pH and osmolarity. It is intended for scientific research only and should not be used for diagnostic, clinical, medical, or in vivo applications.
-
FPR2/ALX in Autoimmune Astrocytopathy
2026-08-25
The reference study identifies FPR2/ALX stimulation with Quin-C1 as an immunomodulatory strategy that limits autoimmune astrocytopathy in mice. Its depletion and pathway-inhibition experiments link protection to microglial and natural killer cell activity involving SYK-AKT signaling, while also defining important limits for translation to human neuroinflammatory disease.
-
Lactate–GPR81 Signaling Drives Insulin-Independent Uptake
2026-08-24
A 2026 Cell Research study identifies lactate as a metabolite that promotes skeletal-muscle glucose uptake independently of insulin through the GPR81–FARP1–RAC1–GLUT4 axis. Its genetic, pharmacological, exercise, and human genetic evidence positions GPR81 as a potential entry point for studying glucose control when insulin signaling is impaired.
-
Mc-Val-Cit-PABC-PNP: ADC Linker Workflow Guide
2026-08-24
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC peptide linker for research workflows that require protease-responsive payload release in lysosomal environments. It is compatible with DMSO-based handling but is insoluble in water and ethanol, and it is not intended for diagnostic, therapeutic, or other clinical use.
-
Pronase E for Protein Sample Preparation
2026-08-22
Pronase E is a broad-spectrum protease mixture for protein digestion, peptide mapping, and molecular biology sample preparation. The A9953 product provides a specified activity of at least 7000 U/g, while the cited ferroptosis study illustrates how protease-enabled sample preparation can support mechanistic cancer research without implying that Pronase E caused the reported biological effects.
-
Native Protein Gel Electrophoresis: K4142
2026-08-22
Use the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit to resolve acidic proteins while retaining native charge, shape, and biological activity. This practical workflow connects structure-preserving separation with protein identification, purification, enzyme assays, and orthogonal analysis of cancer-cell signaling.
-
Y-27632 ROCK Inhibitor for Colorectal Organoids
2026-08-21
Y-27632 provides a practical way to test how ROCK-dependent adhesion, survival, and actin organization influence patient-derived colorectal organoids. This guide connects selective ROCK1 and ROCK2 inhibition with organoid establishment, apical-out conversion, imaging, and troubleshooting while separating evidence-backed product specifications from assay-development recommendations.
-
Mc-Val-Cit-PABC-PNP ADC Linker Workflow
2026-08-20
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC peptide linker for research workflows involving protease-responsive payload release in lysosomal compartments. It is suited to organic-solvent-based antibody-drug conjugate synthesis and should not be used as a water- or ethanol-based reagent, diagnostic material, or therapeutic product.
-
2,2,2-Trichloroethanol for Protein Analysis
2026-08-20
2,2,2-Trichloroethanol is a soluble small molecule biochemical that can add rapid in-gel protein visualization or controlled protein modification to electrophoresis workflows. Its strongest value in neurobiology is complementary: ex vivo protein analysis can help explain cell-state changes, while DAT imaging provides in vivo evidence of dopaminergic maturation.
-
O-propargyl-puromycin (OPP) for Protein Synthesis
2026-08-19
O-propargyl-puromycin (OPP) converts a short metabolic pulse into a quantitative readout of nascent protein production, making it useful for flow cytometry, imaging, and enrichment workflows. Applied to the Pcbp1–mitochondrial phenotype in B cells, it can distinguish altered translation from changes in steady-state antibody abundance while preserving single-cell resolution.
-
Phosphatase Inhibitor Cocktail for Phosphoproteomics
2026-08-19
Protect phosphorylation-dependent signals from lysis through immunoblotting, immunoprecipitation, kinase assays, and mass spectrometry with a dual-component 100X inhibitor system. Its sequential Tube A/Tube B format supports broad serine/threonine and tyrosine phosphatase control while enabling more faithful analysis of signaling mechanisms such as the OTUD3–cGAS pathway.
-
3-(1-methylpyrrolidin-2-yl)pyridine in Arrhythmia Assays
2026-08-18
Use N2703 as a controlled perturbation variable in adipose–neural–cardiomyocyte co-culture experiments, not as a presumed pathway-specific inhibitor. Its documented solubility and high purity support dose-ranging, compartment-specific testing, and orthogonal validation of signaling changes linked to arrhythmogenesis.
-
Neuroligin 1, D2-MSNs, and Repetitive Behavior
2026-08-18
This study identifies striatal D2 receptor-expressing medium spiny neurons as a cell-type-specific circuit node linking Neuroligin 1 loss to autistic-like repetitive behaviors. Its combination of behavioral analysis, activity manipulation, single-nucleus RNA sequencing, and protein validation implicates excessive PKC signaling in D2-MSN hyperexcitability and distinguishes the activity patterns associated with self-grooming and digging.
-
Phosphatase Inhibitor Cocktail 1 for Metabolic Signaling
2026-08-17
Phosphatase Inhibitor Cocktail 1 helps preserve phosphorylation-dependent information during tissue and cell sample preparation. This article connects inhibitor selection with metabolic heterogeneity in posterior fossa malignancies and provides a practical framework for phosphoproteomic analysis, Western blotting, and kinase assays.
-
Trelagliptin, RUNX2, and Osteoblast Differentiation
2026-08-17
The reference study shows that the DPP-4 inhibitor trelagliptin promotes osteoblastic differentiation and mineralization in MC3T3-E1 cells, with increased RUNX2 and AMPK phosphorylation. Its findings provide a mechanistic preclinical rationale for investigating trelagliptin in bone biology, while remaining insufficient to establish clinical efficacy in osteoporosis.